Browsing by Author "Rodríguez, Pablo "

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Formas de integración de los esclavos negros en las Gobernaciones de Antioquia y Popayán, siglo XVII
    (2022) Montoya Muñoz, Sandra Cristina; Undurraga Schüler, Verónica; Rodríguez, Pablo; Pontificia Universidad Católica de Chile. Instituto de Historia
    Esta tesis pretendió analizar las diversas formas de integración y resistencia de los esclavos negros en las gobernaciones de Antioquia y Popayán durante el siglo XVII. Para ello se analizó la participación de los esclavos negros y afrodescendientes en la Iglesia (cofradías, parroquias, prácticas sacramentales, donaciones a la Iglesia); como también las estrategias matrimoniales y los usos de las vinculaciones sociales con españoles por parte de los esclavos negros y afrodescendientes; así mismo, se estudiaron los usos de la justicia y conocimientos de las normas en las gobernaciones, y finalmente, se examinaron los diferentes mecanismos de resistencia y rebeldía que se gestaron a partir de la integración de los esclavos.
  • Thumbnail Image
    Item
    Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry
    (2023) Walbaum García, Benjamín Vicente; Reyes, José Miguel ; Rodríguez, Pablo ; Muñiz Muñoz, María Sabrina; Medina Araya, Lidia Marjorie; Ibáñez Cáceres, Carolina; Merino Lara, Tomás Rodrigo; Pinto, Mauricio ; Bravo, María Loreto ; Acevedo Claros, Francisco Nicolás; Bennett Laso, José Tomás; Sánchez Rojel, César Giovanni
    Background The addition of cyclin-dependent kinases inhibitors (CDKi) to endocrine therapy (ET) as the first- or second line treatment improves progression-free and overall survival (OS) in hormone receptor-positive, HER2 negative (HR+/HER2-) advanced stage breast cancer (ABC). Our study compared survival rates and prognostic factors in Chilean patients that used palbociclib as first or subsequent (≥second) lines of treatment in a real-world setting.Methods Our retrospective population-cohort study included HR+/HER2- ABC patients. We calculated 5-year OS and performed a multivariate analysis to determine prognostic factors.Results A total of 106 patients were included. Median age was 49 years (19–86), 28.3% (30) had de novo stage IV disease; 63% received palbociclib with ET as first line, 54% of them with aromatase inhibitor over fulvestrant. Median OS for the entire cohort was 99 months and 5-year OS was 69%. Patients that received first line palbociclib had a 5-year OS of 89% versus 43% for ET monotherapy or ≥second line palbociclib (p = 0.0062). Multivariate analysis showed that the year at diagnosis and CDKi timing (first line versus ≥second line) were significantly associated with OS.Conclusion Our real-world data show that first-line CDKi + ET provides a statistically significant benefit in OS versus ≥second line in HR+/HER2- ABC patients.